Company intelligence
PolyPeptide Group
Contract Development & Manufacturing Organization (CDMO) for peptide-based APIs.
About PolyPeptide Group
PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical through to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with a large exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. Find out more about our current vacancies at: https://polypeptide.teamtailor.com/
Verified activity
Signals from PolyPeptide Group
4 published signals
Presence & Recognition
PolyPeptide Group is sponsoring the 38th European Peptide Symposium taking place September 6–11 in Vienna, Austria.
Reported by PolyPeptide Group
Strategy & Corporate Development
PolyPeptide Group is launching a new product line for the global market.
Reported by Sochan Rumthao, Ph.D.
People
PolyPeptide Group hired Aymeric Bange as Operational Excellence Leader for the Braine-l'Alleud site in Belgium.
Reported by Aymeric Bange